Biomarker Testing Startup Funding

What are all the funding deals in the biomarker testing market from August 2025 to July 2026?

The table below lists every disclosed equity round raised by pure-play biomarker testing companies between August 2025 and July 2026. We count as “pure-play” biomarker testing companies those focused on tests and analytics that measure biological signals linked to disease, aging, performance, or health risk.

How active has fundraising been in the biomarker testing market?

As of July 2026, fundraising in the biomarker testing market has been active but uneven. Over the past 12 months, companies raised 22 disclosed equity rounds and $644.44M combined, equal to 1.83 deals per month on average.

The biomarker testing market had a median of 1.5 deals per month, which shows that activity was present but not continuous. September 2025 and February 2026 had no qualifying deals, while December 2025, January 2026, and March 2026 each had four.

Capital flow was much more volatile than deal flow. Monthly capital averaged $53.70M, but the median month raised only $14.65M, which means the average was heavily lifted by one or two large months.

November 2025 was the clearest outlier, with $338.0M raised. That single month was driven mainly by Function Health’s $298M Series B and Elephas Biosciences’ $40M Series B, not by broad market acceleration.

How concentrated has fundraising been in the biomarker testing market?

As of July 2026, fundraising in the biomarker testing market has been highly concentrated. Over the past 12 months, the largest deal represented 46.2% of all disclosed capital, the top 3 deals reached 71.6%, and the top 5 reached 82.3%.

Function Health alone raised $298M, making it the defining capital event in the biomarker testing market. Without that round, total disclosed funding would fall from $644.44M to $346.44M.

The top 10 deals captured 93.5% of all disclosed capital. That leaves only 6.5% of market dollars for the remaining 12 rounds, which confirms a sharp power-law pattern.

This concentration means headline funding totals should be read carefully. The biomarker testing market is not uniformly liquid; it is a market where a few scaled platforms drive most reported dollars.

How much of the biomarker testing funding signal is driven by outliers?

As of July 2026, a large share of the biomarker testing funding signal is driven by outliers. Over the past 12 months, only 3 rounds were above $50M, but those 3 rounds represented 71.6% of all disclosed capital.

Removing rounds above $50M changes the market picture completely. Total capital falls from $644.44M to $182.94M, which means most visible capital depth depends on Function Health, Harbinger Health, and Precede Biosciences.

The average round size was $29.29M, while the median round size was $6.0M. This gap is one of the clearest signs that the biomarker testing market should not be evaluated through average deal size alone.

A more realistic typical financing in this dataset is around $5M to $7M. The $29.29M average describes the influence of large rounds more than the everyday funding environment.

Is the biomarker testing market broad with many targets, or narrow with few fundable companies?

As of July 2026, the biomarker testing market is broad by company formation but narrow by capital allocation. Over the past 12 months, 21 unique companies raised 22 disclosed rounds, but the largest few companies captured most of the dollars.

The deal count shows a visible startup bench. Seed rounds represented 8 of 22 deals, and Series A rounds represented 5 more, so new and early companies kept entering the biomarker testing market.

Capital tells a different story. Series B rounds represented only 6 deals but captured $543.8M, equal to 84.4% of all disclosed capital in the biomarker testing market.

This means the biomarker testing market has many fundable experiments, but only a small number of companies attract scale capital. Investors appear willing to seed new approaches while reserving large checks for companies with clearer validation or distribution.

Is biomarker testing mostly an early-stage formation market or a late-stage scaling market?

As of July 2026, the biomarker testing market is early-stage by deal count and late-stage by capital. Over the past 12 months, Seed and Series A rounds represented 13 deals, but they captured only $80.84M, or 12.5% of total disclosed capital.

Late-stage and growth rounds dominate the funding base. Series B and Growth Equity rounds raised $558.9M across 7 deals, equal to 86.7% of total disclosed capital.

Series B rounds are the center of gravity. They represented 27.3% of deals but 84.4% of dollars, with an average deal size of $90.63M and a median of $51.75M.

This suggests that the biomarker testing market rewards companies that have crossed at least one credibility threshold. That threshold may be consumer adoption, clinical validation, pharma utility, commercialization progress, or a clearer route to reimbursement.

Which categories attract the most investor attention in biomarker testing?

As of July 2026, Blood Biomarker Tests attract the most investor attention in the biomarker testing market. Over the past 12 months, the category raised $369.9M across 8 deals, equal to 57.4% of disclosed capital and 36.4% of deals.

Liquid Biopsy Tests were the second-largest capital category. They raised $180.6M across 4 deals, equal to 28.0% of all disclosed capital and 18.2% of deal count.

Together, Blood Biomarker Tests and Liquid Biopsy Tests represented 85.4% of capital. That shows investor attention is concentrated around blood, molecular testing, oncology workflows, and other areas tied to established clinical or lab infrastructure.

Biomarker Analytics Platforms, Genomic Biomarkers, Aging Biomarker Tests, and Microbiome Testing all appeared in the dataset. But outside blood and liquid biopsy, the biomarker testing market remains more exploratory and less capital intensive.

Which categories attract disproportionately large checks in the biomarker testing market?

As of July 2026, Liquid Biopsy Tests and Blood Biomarker Tests attract disproportionately large checks in the biomarker testing market. Over the past 12 months, their capital share exceeded their deal share, with ratios of 1.54 and 1.58 respectively.

Liquid Biopsy Tests had the strongest median category round size at $39.3M. That reflects investor comfort with oncology, molecular assays, and clinical use cases where biomarker results can directly affect decisions.

Blood Biomarker Tests had an average round size of $46.24M, but its median was only $7.75M. This shows that the category is internally mixed, spanning both scaled consumer platforms and smaller clinical or preventive tests.

Aging Biomarker Tests and Microbiome Testing were the opposite. Together they represented 22.7% of deals but only 2.6% of capital, which suggests investors are still testing those areas rather than underwriting large-scale rollouts.

Which geographies matter most for fundraising in the biomarker testing market?

As of July 2026, North America matters most for fundraising in the biomarker testing market. Over the past 12 months, the region raised $535.7M, equal to 83.1% of total disclosed capital, from 9 deals.

North America did not just produce more money; it produced the largest conviction checks. Its average deal size was $59.52M, and its median was $15.0M, far above Europe’s median of $3.5M.

Asia-Pacific ranked second by capital, with $61.84M across 5 deals. That gave the region 9.6% of disclosed capital and 22.7% of deal count.

Europe produced 7 deals, or 31.8% of all activity, but only $46.5M, or 7.2% of capital. Europe looks important for company formation, but not yet for large-scale commercialization funding.

Is the biomarker testing opportunity set broad or concentrated in one hub?

As of July 2026, the biomarker testing opportunity set is geographically broad by deal count but concentrated by capital. Over the past 12 months, deals appeared in North America, Europe, Asia-Pacific, and the Middle East, but North America captured 83.1% of all dollars.

The biomarker testing market does not look like a single-region company formation story. Europe had 7 deals, Asia-Pacific had 5, and the Middle East had 1, which gives the dataset a wider geographic spread than the capital split suggests.

However, large rounds remain concentrated in North America. Function Health, Harbinger Health, Precede Biosciences, Elephas Biosciences, and Circular Genomics all came from the region and set most of the dollar narrative.

Latin America and Africa were absent from the qualifying disclosed dataset. That likely reflects the market’s dependence on lab infrastructure, payer pathways, clinical validation, and high-income early adopters.

Is biomarker testing a market of small experiments or scaled financings?

As of July 2026, the biomarker testing market is mostly a market of small experiments by deal count, but scaled financings dominate the dollars. Over the past 12 months, 9 deals were under $5M, while only 3 deals were above $50M.

The middle of the market is visible but not dominant. Seven deals were between $5M and $20M, and three deals were between $20M and $50M.

The size distribution explains why the median round size is $6.0M while the average is $29.29M. Most companies are raising modest rounds, but a few scaled platforms reset the headline total.

This is a useful reading rule for the biomarker testing market. A typical company is not raising like Function Health or Harbinger Health; it is usually raising enough to validate a test, expand data, or prove a specific commercial use case.

Who are the investors that appear the most in biomarker testing fundraising?

As of July 2026, repeat investor activity in the biomarker testing market was limited. Over the past 12 months, Seedcamp was the only investor clearly identified across more than one company-level transaction in the disclosed dataset.

Seedcamp appeared in Outpost Bio and Function Health. That makes it the clearest multi-company investor signal in the biomarker testing market during this period.

Other repeat references are weaker because they relate to prior participation rather than multiple new company-level deals inside the dataset. Fireside Ventures appeared in Inito’s 2025 Series B and was also referenced through Inito’s earlier Series A, while NKSquared and Nikhil Kamath had prior Biopeak exposure.

This matters because round announcements usually disclose total round size, not each investor’s exact check. So investor frequency is safer to interpret than investor dollar exposure in the biomarker testing market.

The broader conclusion is that biomarker testing has not yet developed a dense set of repeated specialist investors. Most named investors appear once, and many follow-on rounds look driven by existing insiders or company-specific conviction.

Who is the author of this content?

NEW MARKET PITCH TEAM

We track new markets so founders and investors can move faster

We build living "market pitch" documents for emerging markets: AI, synthetic biology, new proteins, and more. Instead of outdated PDFs or hallucinated LLM answers, our clients get a clean, visual, always-updated view of what's really happening: key players, deals, regulations, and signals that matter. Learn more about us.